Acurastem received a grant to develop ALS therapies targeting SYF2, a regulator of TDP-43, in collaboration with academic research teams.
AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
In March 2024, Kayla Gonzalez started having an odd sensation behind her right kneecap. At first, she didn’t think much of it. Then, the feeling started to spread. Soon, she had weakness in her calf, ...
Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.
As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...
"Watching my mom die of ALS was one of the most awful things I’ve gone through. I don’t want my children to see me suffer ...
LOS ANGELES, March 16, 2026 /PRNewswire/ -- The ALS Network, in partnership with ALS United, today announced that Letters of Intent (LOIs) for ALS research funding will be accepted from March 16 ...
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- ALS United Greater New York increased its financial investment in ALS research throughout 2025, accelerating new approaches in ALS treatment, prevention, and ...
NASHVILLE, Tenn. (WKRN) — The Vanderbilt ALS Research Center continues to work toward an Amyotrophic Lateral Sclerosis cure. The ALS Association defines ALS — also known as Lou Gehrig’s disease — as a ...
HONOLULU (HawaiiNewsNow) - Hundreds gathered to help raise money for amyotrophic lateral sclerosis (ALS) in Kapiolani Park Saturday morning. The ALS Network hosted the 13th Annual Hawaii Walk and Roll ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results